Supporting previous findings of PTOV1 activity associated to more aggressive, potentially resistant stages [8–11], we show that docetaxel resistant prostate cancer cells express increased levels of PTOV1 concomitantly with genes associated to resistance [31, 33–36]. Here, PTOV1 is linked to prostate carcinoma.